TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $11.56 Consensus Target Price from Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $11.56.

Several equities research analysts have recently commented on TLSI shares. Roth Mkm restated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price for the company. Lake Street Capital assumed coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th.

TriSalus Life Sciences Price Performance

Shares of TLSI stock opened at $5.70 on Friday. The stock’s fifty day simple moving average is $5.24 and its 200 day simple moving average is $4.72. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The firm has a market cap of $173.81 million, a price-to-earnings ratio of -2.29 and a beta of 0.51.

Insider Activity

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was acquired at an average cost of $3.97 per share, for a total transaction of $249,998.84. Following the transaction, the insider now owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. This trade represents a 1.02 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Emmett Young purchased 24,000 shares of the business’s stock in a transaction on Monday, January 27th. The stock was bought at an average cost of $5.40 per share, for a total transaction of $129,600.00. Following the purchase, the chief financial officer now owns 24,000 shares of the company’s stock, valued at approximately $129,600. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders bought 117,828 shares of company stock valued at $544,607 in the last quarter. Company insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of large investors have recently added to or reduced their stakes in TLSI. Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock worth $1,023,000 after buying an additional 3,710 shares in the last quarter. Bank of America Corp DE grew its position in TriSalus Life Sciences by 120,471.6% in the fourth quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock valued at $894,000 after purchasing an additional 178,298 shares in the last quarter. Bridgeway Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock valued at $326,000 after acquiring an additional 50,000 shares in the last quarter. MSD Partners L.P. bought a new stake in TriSalus Life Sciences during the third quarter worth about $184,000. Finally, Northern Trust Corp boosted its position in TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after purchasing an additional 5,936 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.